Document text
Principal Investigator: George A Truskey
Organization: DUKE UNIVERSITY
Fiscal Year: 2020
Award: $280,600
Funding agency: National Center for Advancing Translational Sciences
Abstract
The appearance of SARS-CoV-2 in early 2020 has spurred efforts to limit the disease spread and develop
effective treatments. The most promising long-term approach is a vaccine. While some vaccines are entering
accelerated clinical trials, it may take 12 or more months before an effective vaccine is available. Even if
successful, it may not be possible to treat everyone with a vaccine or the effectiveness of the vaccine may be
limited. Given the severity of the disease among a number of those patients, alternative approaches to limit
infection should be developed. The goal of this proposal is to use human cardiac, vascular, and lung alveolar
microphysiological systems (MPS) to identify possible compounds that block SARS-CoV-2 entry into cells and
tissues. While cell binding assays can be used to screen drug candidates, human MPS offer the advantage of
testing promising drug candidates under conditions encountered in the body. We propose a tiered approach in
which primary cells and cells overexpressing angiotensin converting enzyme (ACE2) are used to identify
promising candidates that block SARS-CoV-2 virus entry into cells, and vascular, cardiac, and lung alveolar
MPS are used to provide a robust evaluation of drugs that block SARS-CoV-2 binding. The first tier with
individual cell types enables a rapid screen and the screen with the microphysiological systems enables testing
of the most promising candidates with the tissues most likely to be infected. We will develop the screening
assays using a pseudovirus with the SARS-CoV-2 spike protein. In Aim 1, we will develop an assay for
pseudovirus binding to ACE2 expressing cells by verifying binding and fusion to cells that express ACE2. We
will whether the binding specifically involves the spike protein and determine the levels of binding sites on the
cell types used in subsequent aims. In Aim 2, we will screen individual cells types for molecules that block
entry into the cell of pseudovirus expressing the spike proteins. Potential drug candidates include those that
potentially block spike protein binding (e.g. spike proteins, Captopril, Lisinopril, human recombinant soluble
ACE2, and antibodies to the spike protein or ACE2) and those inhibiting Transmembrane Serine Protease 2
(TMPRSS2), activity (e.g. camostat mesylate, nafamostat mesylate). In Aim 3, we will test most promising
compounds in vascular, cardiac and lung microphysiological systems and compare against results from 2D
studies. We will also examine the relationship between drug blocking and factors that affect ACE2 expression.
Terms: <2019 novel coronavirus><2019-nCoV><AGTR2><AGTR2 gene><AT2><Address><Affect><Alveolar><Angiotensin Converting Enzyme><Angiotensin I-Converting Enzyme><Antibodies><Appearance><Assay><Binding><Binding Proteins><Binding Sites><Bioassay><Biologic Assays><Biological Assay><Blood Vessels><Body Tissues><CD143 Antigens><COVID-19><COVID19><Captopril><Carboxycathepsin><Cardiac><Cardiac Muscle Cells><Cardiac Myocytes><Cardiocyte><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Cathepsins><Cell Body><Cell Line><CellLine><Cells><Clinical Trials><Combining Site><Dipeptidyl Peptidase A><Disease><Disorder><Dose><Drug Evaluation><Drug Evaluation Studies><Drug Screening><Drugs><Endocytosis><Endothelial Cells><Epithelial Cells><Epitheliasin Gene><Esteroproteases><Exocytosis><Goals><Health><Heart Muscle Cells><Heart Vascular><Heart myocyte><Human><Individual><Infection><International><Kininase A><Kininase II><Leiomyocyte><Ligand Binding Protein><Ligand Binding Protein Gene><Lip><Lip structure><Lisinopril><Lung><Lung Alveolar Epithelia><Lung Respiratory System><Medication><Mesylates><Methanesulfonates><Methylenesulfonates><Modeling><Modern Man><Molecular Interaction><Non-Polyadenylated RNA><PRSS10><Patient Care><Patient Care Delivery><Patients><Peptidases><Peptide Hydrolases><Peptidyl-Dipeptidase A><Pharmaceutic Preparations><Pharmaceutical Preparations><Prinivil><Process><Protease Gene><Proteases><Protein Binding><Proteinases><Proteins><Proteolytic Enzymes><RNA><RNA Gene Products><Reactive Site><Receptor Protein><Recombinants><Research Resources><Resources><Ribonucleic Acid><SARS><SARS coronavirus disease><SARS-CoV disease><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Serine Endopeptidases><Serine Protease><Serine Protein Hydrolases><Serine Proteinases><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe acute respiratory syndrome coronavirus 2><Severity of illness><Smooth Muscle Cells><Smooth Muscle Myocytes><Smooth Muscle Tissue Cell><Specificity><Strains Cell Lines><System><TMPRSS2><TMPRSS2 gene><Testing><Tissues><Vaccines><Vascular Endothelium><Viral><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus><Wuhan coronavirus><Zestril><alleviate symptom><alternative treatment><alveolar epithelium><ameliorating symptom><base><blocking factor><bound protein><cardiomyocyte><cell type><circulatory system><corona virus disease 2019><coronavirus disease 2019><cultured cell line><decrease symptom><design><designing><disease severity><drug candidate><drug detection><drug testing><drug/agent><effective therapy><effective treatment><experience><fewer symptoms><human tissue><iPS><iPSC><iPSCs><in vivo><induced pluripotent stem cell><insight><mesilate><methane sulfonate><microphysiologic model><microphysiologic platform><microphysiologic system><microphysiology model><microphysiology platform><microphysiology system><overexpress><overexpression><prevent><preventing><pulmonary><receptor><reduce symptoms><relieves symptoms><response><screening><symptom alleviation><symptom reduction><symptom relief><vaccine effectiveness><vascular><virus protein>